Chief Executive Officer
Joern has explored how humans learn, first as a linguist and then as a computational psychologist scientist during his Masters at Oxford, where he created deep learning models of the brain.
In his PhD at the University of Texas at Austin he flipped his research on its head and studied how humans from diverse backgrounds learn to improve AI. He spent a month each year in an indigenous community in Oaxaca, Mexico and then channeled his insights to build state of the art computational models - one example is a model that detects irony in social media posts.
He met Marco while working as a Lead Data Scientist in London and got so fascinated with Genomics and the ideas that would become biotx.ai that he quit his job and became a full time founder.
Chief Technology Officer
Charles is our CTO. With his PhD and Post-Doc in Computational Genomics from the University of Cambridge, he excellently ties together Marco's drug development knowledge and Joern's machine learning background.
In addition to his outstanding academic contributions, Charles published in Nature, he is a software development veteran. Charles took the prototypes that Joern built and turned them into production quality software that scales to the platform level.
Chief Operating Officer
Christian is our Sales and Business Development Superstar. Before joining biotx.ai in 2020, Christian lead the European and Middle-Eastern operations at Medidata, a large provider for clinical trials software used by all major pharma companies, that was recently acquired for $5.8 billion.
Prior to Medidata Christian was a VP at Salesforce in the Life Sciences department. His expertise from both previous roles has already had a positive impact on structuring biotx.ai's sales strategy.
Chief Scientific Officer
Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.
During his time at Cambridge, Marco received a Marie-Curie fellowship, as well as a stipend from the Gates Foundation to do his own research. Marco worked with excellent people like Chris Abell (who would later become vice chancellor) and Tom Blundell, the founders of Astex, a fragment based drug discovery company that was acquired for $866 Million.
His work with Chris and Tom opened his eyes to the possibilities of launching his own company, as well as to the limitation of traditional approaches to drug development: The inability to predict clinical efficacy. Solving this problem became the mission of biotx.ai.
Justin takes great interest in philosophy, language and computer science. During his PhD at the University of Texas at Austin he build Natural Language Processing models that are able to understand the temporal order of events in written text, i.e. what happens first, what happens second and so on.
His NLP skills are instrumental to the data mining aspects of the biotx.ai platform, but Justin has also become a master in genomics in record time, improving and implementing our core algorithms - have a look at our paper where he is first author here: https://www.frontiersin.org/articles/10.3389/fgene.2021.744557/full.
Outside of science Justin spends a lot of time on music: He has been an on and off semi-professional musician and plays almost every instrument in existence.
Margaretha is a data scientist who, for personal reasons, transitioned to bioinformatics after already having obtained a degree in art therapy. She received her BSc from the Frei University of Berlin and got practical experience prior to biotx.ai through her internships at the Max Planck Institute for Molecular Genetics where she worked on Next Generation Sequencing Data, as well as the now rather famous Robert Koch Institute, where she worked as a software developer.
At biotx.ai, among other things, she has made a significant impact on the reporter tool and was responsible for one of the most fundamental steps of every single analysis we conducted - phenotype selection from biobank data.
Hannes is a data scientist with an interdisciplinary background in bioinformatics, drug discovery, and protein biochemistry. After receiving a Master degree in Molecular Life Science from the University of Lübeck, he worked at the Max Planck Insitute of Colloids and Interfaces where he identified proteins’ allosteric binding sites for small molecule fragments.
In order to complement his life science skills with a computational point of view, Hannes completed a Master program in Bioinformatics at the Free University Berlin. Hannes started working for biotx.ai in 2020 where translates his scientific experience and computational skills into practical applications.
Outside of science Hannes spends a lot of time on football grounds: a passionate soccer player for all of his life, he recently picked up Gaelic football and represents the German national team.
Radi is a creative developer from Toronto, Canada, who loves experimenting with tech.
He graduated from York University with a degree in Digital Media and Computational Arts.
With knowledge of Adobe CC, as well as HTML/CSS/JS, Radi freelanced as a graphic designer and UX/UI developer for a couple of years after graduation, before moving to Berlin, and joining the biotx.ai team shortly after.
If you like any of the graphics on our website, there is a good chance that Radi made them.
Alex continually strives towards improving patient welfare with healthcare data, making him a perfect fit for the biotx.ai data science team.
He also has a range of experiences to show for that come in handy.
At the Usher Institute for Population Health at the University of Edinburgh he worked towards understanding global surgery outcomes for policymaking, created detection models for breast cancer based on whole-slide histopathology slides.
Like many in our team, he has worked on exciting projects in other areas, like Natural Language Processing of social media messages.
Alex also brings industry experience from working with a biotech startup to translate the latest research in toxicity to a product, which can facilitate water safety.
These experiences put him in prime position to develop services and platforms to help translate data to action.
Valentin is a working student at biotx.ai. He has been involved in mathematics since his youth, during which he was active in a high-ability group. After graduating from high school, however, he decided to dedicate himself to the novel research field of bioinformatics.
Since last year, he has his bachelor's degree from the Humboldt University in Berlin in his pocket and decided to directly pursue a master's degree in computer science.
At biotx.ai he is supporting the development team in building the internal graph database.
Valentin also dreams of founding his own startup one day. Therefore, he is very proud to be part of realizing biotx.ai's vision.
Board of Directors
Harald has held high ranking position, including CEO, CFO and Chairman at a plethora of publicly traded companies including Fresenius, Karstadt and Kion Group.
As an Angel Investor he has been supporting German startups in the health space for many years.
Harald was our first major investor and believed in our vision, when it was just that, a vision. His help has been instrumental in getting where we are now.
Harald's Wikipedia entry: https://de.wikipedia.org/wiki/Harald_Pinger
Board of Directors
Hussein is one of the two original partners at Hoxton Ventures, a fund located in London, operated according to the Silicon Valley model. Out of the less than 20 companies that Hoxton had in their portfolio at the time of their investment in biotx.ai, three have now reached unicorn status and of those two have had successful IPOs.
This means that we are in good company and have lots to live up to. Hussein's presence on our board assures that we stay on track to reach our grand vision.
Hoxton Ventures: https://www.hoxtonventures.com/
Being a medical doctor with decades of experience in the biotech industry, Giancarlo understands the challenges and opportunities that small biotech firms face when bringing their treatments to market. Giancarlo's investment banking and brokering experience gives him unique insight into how pharma companies operate, making him ideally suited to help small biotech firms such as biotx.ai broker deals with larger companies. Welcome, Giancarlo, and off to new heights.
Andrew Thompson is a Silicon Valley based Chief Executive, entrepreneur and investor with a 30-year track record of successful technology-based innovation. As a Founder and Chief-Executive he has raised over $750M in private, public and corporate capital for first-in-category companies and personally negotiated three successful M&A transactions with Fortune 50 enterprises. In addition to his entrepreneurial career, he has been a Board Member at Stanford University Libraries for 20 years working on digital innovations that increase “speed to knowledge”. He is a founder and Board Member at Summit Schools, a charter school network operating in all 50 US states that uses digital tools to deliver personalized learning solutions. Andrew is an Associate and Strategic Advisory Board Member of the Creative Destruction Lab and Board Member and Advisor to several techbio companies in Europe, Asia and the United States.
George Savage is a Silicon Valley-based entrepreneur and investor with a successful track-record of first-in-category medical product innovation. As a founder, board member and C-level executive he has successfully taken multiple revolutionary ideas through the full lifecycle from conception to funding, development, regulatory approval, commercialization and exit. Dr. Savage pioneered catheter-based minimally-invasive surgery inside the heart, proceeding from concept to FDA premarket approval in only three years. In 2014, he was named one of the 100 most inspiring people in the pharmaceutical industry by PharmaVoice. In 2016, Dr. Savage was elected a fellow of the American Institute of Medical and Biological Engineering “for innovation and medical device entrepreneurship and in advancement of transformative digital health technologies to reduce healthcare cost and improve personalized medicine.” He is a mentor of the Creative Destruction Lab and advises companies based in the United States, Europe and Asia.